Selvita (SLV) Stock Overview
Operates as a contract research organization worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SLV from our risk checks.
SLV Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Selvita S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł44.00 |
| 52 Week High | zł50.80 |
| 52 Week Low | zł26.50 |
| Beta | -0.064 |
| 1 Month Change | -4.56% |
| 3 Month Change | 5.77% |
| 1 Year Change | -4.35% |
| 3 Year Change | -46.34% |
| 5 Year Change | -24.14% |
| Change since IPO | 109.52% |
Recent News & Updates
Recent updates
Further Upside For Selvita S.A. (WSE:SLV) Shares Could Introduce Price Risks After 27% Bounce
Nov 27
Selvita S.A. (WSE:SLV) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Jul 25A Piece Of The Puzzle Missing From Selvita S.A.'s (WSE:SLV) 28% Share Price Climb
May 14Is Selvita (WSE:SLV) Using Too Much Debt?
Apr 29Is Selvita (WSE:SLV) Using Too Much Debt?
Sep 26It's Unlikely That The CEO Of Selvita S.A. (WSE:SLV) Will See A Huge Pay Rise This Year
Jun 14Earnings Report: Selvita S.A. Missed Revenue Estimates By 7.1%
May 26Selvita's (WSE:SLV) Solid Earnings May Rest On Weak Foundations
Apr 03Selvita S.A. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 01Selvita S.A. (WSE:SLV) Analysts Just Cut Their EPS Forecasts Substantially
Oct 07We Think Selvita (WSE:SLV) Can Stay On Top Of Its Debt
Sep 28Here's Why Selvita (WSE:SLV) Has Caught The Eye Of Investors
Jun 02Selvita (WSE:SLV) Seems To Use Debt Quite Sensibly
Jun 09These 4 Measures Indicate That Selvita (WSE:SLV) Is Using Debt Reasonably Well
Feb 23If You Like EPS Growth Then Check Out Selvita (WSE:SLV) Before It's Too Late
Mar 31Here's What Selvita S.A.'s (WSE:SLV) Shareholder Ownership Structure Looks Like
Feb 25Here's Why We Don't Think Selvita's (WSE:SLV) Statutory Earnings Reflect Its Underlying Earnings Potential
Jan 22
Is Now The Time To Put Selvita (WSE:SLV) On Your Watchlist?
Dec 25Did You Miss Selvita's (WSE:SLV) Impressive 113% Share Price Gain?
Dec 02Shareholder Returns
| SLV | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | 6.0% | -3.1% | -1.0% |
| 1Y | -4.3% | -11.4% | 31.0% |
Return vs Industry: SLV exceeded the Polish Life Sciences industry which returned -11.4% over the past year.
Return vs Market: SLV underperformed the Polish Market which returned 31% over the past year.
Price Volatility
| SLV volatility | |
|---|---|
| SLV Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in PL Market | 10.5% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: SLV has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: SLV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 969 | Boguslaw Sieczkowski | selvita.com |
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, immunology, neurology, respiratory, and other.
Selvita S.A. Fundamentals Summary
| SLV fundamental statistics | |
|---|---|
| Market cap | zł816.82m |
| Earnings (TTM) | -zł2.89m |
| Revenue (TTM) | zł373.90m |
Is SLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLV income statement (TTM) | |
|---|---|
| Revenue | zł373.90m |
| Cost of Revenue | zł73.76m |
| Gross Profit | zł300.14m |
| Other Expenses | zł303.03m |
| Earnings | -zł2.89m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 80.27% |
| Net Profit Margin | -0.77% |
| Debt/Equity Ratio | 34.4% |
How did SLV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 19:40 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Selvita S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Sylwia Jaskiewicz | Dom Maklerski Banku Ochrony Srodowiska S.A. |